"Where name and image meet"--the argument for "adrenaline".

A European Commission directive requiring member states to use recommended international non-proprietary names for all drugs is soon to be implemented. For most drug names there will be little or no change. For around two dozen drugs the changes are more important; these will be dual labelled during...

Full description

Bibliographic Details
Main Author: Aronson, J
Format: Journal article
Language:English
Published: 2000
_version_ 1797082087698726912
author Aronson, J
author_facet Aronson, J
author_sort Aronson, J
collection OXFORD
description A European Commission directive requiring member states to use recommended international non-proprietary names for all drugs is soon to be implemented. For most drug names there will be little or no change. For around two dozen drugs the changes are more important; these will be dual labelled during the five year changeover period. It is intended that adrenaline (British approved name) will be changed to epinephrine (recommended international non-proprietary name). The strong arguments for persuading the European Union to resist this particular change are based on usage, history, etymology, and, most importantly, risk of clinical errors.
first_indexed 2024-03-07T01:23:15Z
format Journal article
id oxford-uuid:91141996-e359-4ec0-8ae3-e8fd958a6c9a
institution University of Oxford
language English
last_indexed 2024-03-07T01:23:15Z
publishDate 2000
record_format dspace
spelling oxford-uuid:91141996-e359-4ec0-8ae3-e8fd958a6c9a2022-03-26T23:16:09Z"Where name and image meet"--the argument for "adrenaline".Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:91141996-e359-4ec0-8ae3-e8fd958a6c9aEnglishSymplectic Elements at Oxford2000Aronson, JA European Commission directive requiring member states to use recommended international non-proprietary names for all drugs is soon to be implemented. For most drug names there will be little or no change. For around two dozen drugs the changes are more important; these will be dual labelled during the five year changeover period. It is intended that adrenaline (British approved name) will be changed to epinephrine (recommended international non-proprietary name). The strong arguments for persuading the European Union to resist this particular change are based on usage, history, etymology, and, most importantly, risk of clinical errors.
spellingShingle Aronson, J
"Where name and image meet"--the argument for "adrenaline".
title "Where name and image meet"--the argument for "adrenaline".
title_full "Where name and image meet"--the argument for "adrenaline".
title_fullStr "Where name and image meet"--the argument for "adrenaline".
title_full_unstemmed "Where name and image meet"--the argument for "adrenaline".
title_short "Where name and image meet"--the argument for "adrenaline".
title_sort where name and image meet the argument for adrenaline
work_keys_str_mv AT aronsonj wherenameandimagemeettheargumentforadrenaline